Former President Donald Trump has unveiled the TrumpRx website, a new initiative aimed at providing discounts on prescription drugs. This announcement follows a recent deal with Pfizer, which will result in lower prices for select medications in the U.S. and a direct-to-consumer buying platform. While some analysts suggest that this deal could benefit patients and encourage market competition, others warn that it might ultimately serve the interests of large pharmaceutical companies. Local pharmacists have expressed mixed reactions, and industry experts emphasize the need for further changes in pharmaceutical pricing strategies. As the TrumpRx site launches, it raises questions about the potential impact on drug costs and data privacy concerns. Overall, Trump’s approach to drug pricing is facing scrutiny amid a government shutdown and ongoing debates about healthcare reform.